Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant

Clin Microbiol Infect. 2004 Mar;10(3):255-7. doi: 10.1111/j.1198-743x.2004.00837.x.

Abstract

Caspofungin, in association with other antifungal drugs, was administered as rescue therapy in two cases of documented and one case of possible invasive fungal infection in children with acute leukaemia or undergoing allogeneic bone marrow transplant. The combined therapy was well-tolerated and seemed to be effective in all three patients. A combination antifungal therapy including caspofungin could represent an effective therapy for children with invasive mycoses refractory to single-agent antifungal therapy.

MeSH terms

  • Adolescent
  • Amphotericin B / administration & dosage*
  • Bone Marrow Transplantation / adverse effects*
  • Caspofungin
  • Child
  • Drug Therapy, Combination
  • Echinocandins
  • Humans
  • Leukemia / complications*
  • Lipopeptides
  • Liposomes
  • Male
  • Peptides / administration & dosage*
  • Peptides, Cyclic*
  • Pneumonia / drug therapy*
  • Pyrimidines / administration & dosage*
  • Transplantation, Homologous
  • Triazoles / administration & dosage*
  • Voriconazole

Substances

  • Echinocandins
  • Lipopeptides
  • Liposomes
  • Peptides
  • Peptides, Cyclic
  • Pyrimidines
  • Triazoles
  • Amphotericin B
  • Caspofungin
  • Voriconazole